Two biotechs to keep an eye on
snippet
Two small biotechs are drawing attention from analysts and investors-Amryt Pharma and Eloxx Pharmaceuticals.
Source
GoinPharma
Headline
Aegerion expects to initiate pediatric study of lomitapide in 2014
Source
Yahoo/Fly on the Wall
Aegerion says FDA approves Juxtapid, a treatment for a rare high cholesterol disorder
Source
Yahoo/AP
New drug holds promise as therapy for rare and deadly cholesterol disorder
Source
Equities.com
Aegerion's Lomitapide - FDA Approval, Strong Launch, Stock Price Increase Anticipated
Source
Seeking Alpha